PL3297644T3 - Metody terapii zaburzeń ze spektrum autyzmu i powiązanych objawów - Google Patents

Metody terapii zaburzeń ze spektrum autyzmu i powiązanych objawów

Info

Publication number
PL3297644T3
PL3297644T3 PL16800592T PL16800592T PL3297644T3 PL 3297644 T3 PL3297644 T3 PL 3297644T3 PL 16800592 T PL16800592 T PL 16800592T PL 16800592 T PL16800592 T PL 16800592T PL 3297644 T3 PL3297644 T3 PL 3297644T3
Authority
PL
Poland
Prior art keywords
methods
autism spectrum
spectrum disorder
associated symptoms
treating autism
Prior art date
Application number
PL16800592T
Other languages
English (en)
Inventor
James Adams
Rosa Krajmalnik-Brown
Dae-Wook Kang
Michael J. Sadowsky
Alexander KHORUTS
Thomas J. Borody
Original Assignee
Arizona Board Of Regents On Behalf Of Arizona State University
Regents Of The University Of Minnesota
Finch Therapeutics Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board Of Regents On Behalf Of Arizona State University, Regents Of The University Of Minnesota, Finch Therapeutics Holdings Llc filed Critical Arizona Board Of Regents On Behalf Of Arizona State University
Publication of PL3297644T3 publication Critical patent/PL3297644T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL16800592T 2015-05-22 2016-05-23 Metody terapii zaburzeń ze spektrum autyzmu i powiązanych objawów PL3297644T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165556P 2015-05-22 2015-05-22
PCT/US2016/033747 WO2016191356A1 (en) 2015-05-22 2016-05-23 Methods for treating autism spectrum disorder and associated symptoms
EP16800592.4A EP3297644B1 (en) 2015-05-22 2016-05-23 Methods for treating autism spectrum disorder and associated symptoms

Publications (1)

Publication Number Publication Date
PL3297644T3 true PL3297644T3 (pl) 2022-05-30

Family

ID=57325991

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16800592T PL3297644T3 (pl) 2015-05-22 2016-05-23 Metody terapii zaburzeń ze spektrum autyzmu i powiązanych objawów

Country Status (15)

Country Link
US (5) US20160339065A1 (pl)
EP (2) EP3297644B1 (pl)
JP (2) JP6856968B2 (pl)
KR (2) KR102534545B1 (pl)
CN (3) CN114470009A (pl)
AU (2) AU2016268158B2 (pl)
BR (1) BR112017024777A2 (pl)
CA (1) CA2986485A1 (pl)
DK (1) DK3297644T3 (pl)
ES (1) ES2909456T3 (pl)
HU (1) HUE058209T2 (pl)
NZ (2) NZ737786A (pl)
PL (1) PL3297644T3 (pl)
PT (1) PT3297644T (pl)
WO (1) WO2016191356A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
EP3072524B1 (en) 2010-10-07 2018-01-17 California Institute Of Technology Probiotic therapies for autism
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6679309B2 (ja) 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
EP3375447A1 (en) 2013-06-05 2018-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
CA2966363A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP3297644B1 (en) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10828340B2 (en) * 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
EP3370748B1 (en) 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
EP3465212A4 (en) * 2016-05-23 2020-01-08 California Institute of Technology REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US20170360848A1 (en) * 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018089794A1 (en) * 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject
EP3558329B1 (en) 2016-12-20 2024-01-31 The Regents of The University of California Compositions and methods for inhibiting seizures
EP3579836B1 (en) * 2017-02-09 2021-12-15 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
JP2020513018A (ja) 2017-04-05 2020-04-30 クレストヴォ・ホールディングス・エルエルシー パーキンソン病（ｐｄ）および関連する障害を治療するための組成物および方法
EP3624782A4 (en) 2017-05-15 2021-05-05 Axial Biotherapeutics, Inc. INHIBITORS OF MICROBIALLY INDUCED AMYLOID
RS61872B1 (sr) * 2017-05-22 2021-06-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． 健康な腸バリアを維持及び回復するための組成物及び方法
WO2019033142A1 (en) * 2017-08-15 2019-02-21 Borody Thomas J COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OF AUTISM
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020037364A1 (en) * 2018-08-20 2020-02-27 Murdoch Childrens Research Institute Behavioural treatment
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN109276711B (zh) * 2018-10-18 2022-04-05 杭州睿道医药科技有限公司 锰型高稳定性超氧化物歧化酶在改善自闭症中的应用及产品
CA3122338A1 (en) * 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
CN115297859A (zh) * 2019-05-31 2022-11-04 托马斯·朱利叶斯·波洛迪 用于结肠微生物群移植的装置、组合物和方法
AU2020309729A1 (en) * 2019-07-05 2022-01-27 4D Pharma Research Limited Compositions comprising bacterial strains
AU2020310947A1 (en) 2019-07-11 2021-12-23 Thomas Julius Borody Method for gut mucosa preparation to enhance microbial engraftment
JP2022547330A (ja) * 2019-09-13 2022-11-11 フィンチ セラピューティクス ホールディングス エルエルシー 自閉症スペクトラム障害を治療するための組成物および方法
CA3151544A1 (en) * 2019-09-19 2021-03-25 Illana Gozes Methods for diagnosing and treatment monitoring of adnp-deficient patients
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder
CN111455076B (zh) * 2020-04-17 2022-10-21 济南市儿童医院 用于儿童孤独症评估的口腔菌群微生物
TW202214273A (zh) * 2020-06-15 2022-04-16 香港中文大學 細菌在孩童發育評估和治療的應用
CN112029844B (zh) * 2020-07-30 2021-10-19 中国医学科学院病原生物学研究所 肠道微生物在诊断肌张力障碍症中的应用
KR102351147B1 (ko) 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023056419A1 (en) * 2021-09-30 2023-04-06 The General Hospital Corporation Systems and methods for assessing medical conditions such as inflammation, autoimmunity, and autism spectrum disorder (asd) and treatments thereof
KR20230118736A (ko) 2022-02-04 2023-08-14 주식회사 히포티앤씨 자폐 스펙트럼 장애 치료를 위한 인공지능 기반 맞춤형 콘텐츠 생성 방법
WO2024026561A2 (en) 2022-08-01 2024-02-08 Novel Biome Solutions Inc. Fecal microbiota transplant methods of manufacture
CN116211895A (zh) * 2023-02-08 2023-06-06 上海承葛医药科技有限公司 一种治疗自闭症的菌群组合物及应用

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5528E (fr) 1905-03-16 1906-05-02 Farcot Freres Et Cie Soc Perfectionnements aux turbines à vapeur ou à gaz
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
FR1275M (fr) 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
NL294835A (pl) 1962-07-19 1900-01-01
FR2828M (fr) 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
GB1271674A (en) 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (pl) 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4536409A (en) 1981-01-23 1985-08-20 American Can Company Oxygen scavenger
US4394377A (en) 1981-07-31 1983-07-19 Syntex (U.S.A.) Inc. Ruminant animal performance by co-administering choline and propionate enchancers
US4452779A (en) 1982-02-03 1984-06-05 Cockerill Vernon Composition and method of treating lactating mammals
FI840816A0 (fi) 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
JPS615022A (ja) 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
US4892731A (en) 1986-12-11 1990-01-09 Tadashi Arai Biological intestinal antiseptics
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
US4948734A (en) 1987-08-12 1990-08-14 Mycogen Corporation Novel isolates of bacillus thuringiensis having activity against nematodes
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5266315A (en) 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
JP3047143B2 (ja) 1992-04-24 2000-05-29 堀井薬品工業株式会社 腸管洗浄液用組成物及び腸管洗浄液
JP3850891B2 (ja) 1994-03-01 2006-11-29 ゼリア新薬工業株式会社 緩下効果を有する組成物
JPH07242557A (ja) 1994-03-03 1995-09-19 Ss Pharmaceut Co Ltd 乳酸菌含有瀉下薬組成物
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
DE760848T1 (de) 1994-05-26 1997-08-28 Bracco Spa Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5858356A (en) 1995-12-21 1999-01-12 Abbott Laboratories Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
WO1998013068A1 (fr) 1996-09-26 1998-04-02 Vladimir Borisovich Kuperman Medicament prophylactique 'trisan'
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
US7374753B1 (en) 1997-06-03 2008-05-20 Ganeden Biotech, Inc. Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US5902743A (en) 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
CN1300318A (zh) 1998-05-06 2001-06-20 中村启次郎 含有性质不同且彼此共生的微生物和其代谢物的微生物培养物,含有该培养物活性组分的载体和吸附剂及其用途
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
AT407008B (de) 1998-08-06 2000-11-27 Viernstein Helmut Dr Formulierungen mit probiotisch wirksamen mikroorganismen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
CZ2001951A3 (cs) 1998-09-17 2001-11-14 Baxter Healthcare S. A. Prostředky obsahující streptokokový Cbeta protein
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
IL143632A0 (en) 1998-12-11 2002-04-21 Urex Biotech Inc Pharmaceutical compositions containing lactobacillus
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE60040214D1 (de) 1999-02-26 2008-10-23 Shionogi & Co Kaubare weichkapseln mit verbesserten verabreichungseigenschaften sowie verfahren zu deren herstellung
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US6756032B1 (en) 2000-07-12 2004-06-29 The Procter & Gamble Company Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7214370B2 (en) 2000-12-18 2007-05-08 Probiohealth, Llc Prebiotic and preservative uses of oil-emulsified probiotic encapsulations
US6790453B2 (en) 2001-03-14 2004-09-14 Mccormick & Company, Inc. Encapsulation compositions and process for preparing the same
US7815956B2 (en) 2001-04-27 2010-10-19 Pepsico Use of erythritol and D-tagatose in diet or reduced-calorie beverages and food products
DE60237087D1 (de) 2001-06-01 2010-09-02 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
AU2002315779B2 (en) 2001-07-05 2007-03-22 Wakunaga Pharmaceutical Co.,Ltd Soft capsules
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
GEP20064022B (en) 2002-04-05 2007-01-10 Euro Celtique Sa Pharmaceutical formulations comprising oxycodone and naloxone
CA2391422A1 (en) 2002-07-12 2004-01-12 David William Molloy Rifampin (rifadin, rimactone, rifampicin) and doxycycline, (doryx, vibramycin) and the tetracyclines and other compounds currently classified as antibiotics and anti-tuberculous drugs as a treatment to prevent, modify disease progression and/or improve symptoms for neurodegenerative diseases including alzheimers disease, lewy body dementia, schizophrenia,...
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
WO2005017095A2 (en) 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20060177424A1 (en) 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US8016816B2 (en) 2003-09-09 2011-09-13 Convatec Technologies Inc. Fecal management appliance and method and apparatus for introducing same
US7541091B2 (en) 2004-05-18 2009-06-02 M & G Usa Corporation Compartmentalized resin pellets for oxygen scavenging
ES2290762T3 (es) 2004-08-05 2008-02-16 Anidral S.R.L. Cepas bacterianas de bifidobacterium que producen acido folico, sus formulaciones y utilizacion.
EP1800688A1 (en) 2004-08-05 2007-06-27 Anidral S.R.L. Folic acid producing bifidobacterium bacterial strains, formulations and use thereof
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
TW200626160A (en) * 2004-09-23 2006-08-01 Merz Pharma Gmbh & Co Kgaa Memantine for the treatment of childhood behavioral disorders
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
WO2006127355A2 (en) 2005-05-20 2006-11-30 Dow Global Technologies Inc. Oral drug compliance monitoring using radio frequency identification tags
US20060275223A1 (en) 2005-06-02 2006-12-07 Burr James B Erythritol compositions for teeth and gums
TWI362949B (en) 2005-09-13 2012-05-01 Bion Tech Inc Intestines dissolving nature is able to bear the hydrochloric acid in gastric juice and wrap up the benefit covered and grow the fungus of makes up
DE602006018529D1 (de) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
JP5006567B2 (ja) 2006-04-14 2012-08-22 花王株式会社 口腔用固形製剤
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
JP2008106066A (ja) 2006-09-25 2008-05-08 Tashiro Yasuaki サポニン及び生菌を含有する組成物
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008105715A2 (en) 2007-03-01 2008-09-04 Probi Ab Use of lactobacillus plantarum for increasing bacterial diversity
KR20090127180A (ko) 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
BRPI0810087A2 (pt) 2007-03-28 2014-10-21 Alimentary Health Ltd Cepas de bifidobacterium probióticas
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
JP2010529073A (ja) 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア チュアブル錠及びトローチ剤製造のための医薬製剤
US10406105B2 (en) 2007-06-06 2019-09-10 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
CN103691530A (zh) 2007-07-27 2014-04-02 卡吉尔公司 多元醇的微粉化
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009032560A1 (en) 2007-08-31 2009-03-12 Invista Technologies S.Ar.L. Oxygen scavenging plastic compositions
US20100233278A1 (en) 2007-09-27 2010-09-16 Akiko Ookawa Rapidly disintegrating solid preparation
EP2572705B1 (en) 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
CN101896161A (zh) 2007-10-19 2010-11-24 普渡（大学）研究基金 结晶化合物的固体制剂
EP2203551B1 (en) 2007-10-20 2013-08-21 Université de Liège Bifidobacterial species
CA2740434C (en) 2007-10-26 2017-11-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
JP5258268B2 (ja) 2007-11-19 2013-08-07 フロイント産業株式会社 球形粒の製造方法
JP5352474B2 (ja) 2007-12-28 2013-11-27 沢井製薬株式会社 口腔内崩壊錠およびその製造方法
CN101496819A (zh) 2008-01-31 2009-08-05 青岛东海药业有限公司 真杆菌、梭菌制剂及其应用
KR100913405B1 (ko) 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
US20100178413A1 (en) 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
WO2010103132A1 (es) 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
US20100255231A1 (en) 2009-04-01 2010-10-07 Multisorb Technologies, Inc. Oxygen scavenging films
CN102414310B (zh) 2009-04-30 2015-05-06 阿克图杰尼斯公司 用于冷冻干燥乳酸菌的冷冻保护剂
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
WO2010138439A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multiparticulate controlled-release selective serotonin reuptake inhibitor formulations
CN201441672U (zh) 2009-07-14 2010-04-28 赵伟华 一次性灌肠装置
US20110045222A1 (en) 2009-08-19 2011-02-24 Eastman Chemical Company Oxygen-scavenging polymer blends suitable for use in packaging
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
JP2013507394A (ja) 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
WO2011058536A1 (en) 2009-11-11 2011-05-19 Alimentary Health Limited A bifidobacterium strain
DK2523661T3 (en) * 2010-01-15 2017-07-03 Inserm (Institut Nat De La Santé Et De La Rech Médicale) NKCC inhibitors for the treatment of autism
US20110218216A1 (en) 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical composition of donepezil
ES2730828T3 (es) 2010-02-01 2019-11-12 Rebiotix Inc Bacterioterapia para la colitis por Clostridium difficile
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
BR112012022775A2 (pt) 2010-03-10 2016-07-19 Nogra Pharma Ltd composições para a lavagem, do cólon e métodos para a produção e utilização das mesmas
US9707207B2 (en) * 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
CA2813080A1 (en) 2010-10-04 2012-04-12 British Columbia Cancer Agency Branch Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
EP3072524B1 (en) 2010-10-07 2018-01-17 California Institute Of Technology Probiotic therapies for autism
WO2014152484A1 (en) * 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
US20150374761A1 (en) 2011-03-09 2015-12-31 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013053836A1 (en) 2011-10-11 2013-04-18 Quantum Pharmaceuticals Sa Composition comprising anaerobically cultivated human intestinal microbiota
CN104160014A (zh) 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2609814A1 (en) 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
CN104662425B (zh) 2012-05-02 2017-10-10 查尔斯河实验室公司 活性染色方法
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP6679309B2 (ja) * 2012-08-29 2020-04-15 カリフォルニア インスティチュート オブ テクノロジー 自閉症スペクトラム障害の診断および処置
JP2015535280A (ja) 2012-11-01 2015-12-10 レイクスユニフェルシテイト フローニンゲン 胃腸管において有益な細菌を刺激する方法及び組成物
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en) * 2012-11-26 2014-05-30 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
EP2956006A4 (en) 2013-02-04 2017-02-22 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US20140243175A1 (en) 2013-02-26 2014-08-28 Ming-Chih Huang Fitness chair
CA3013541C (en) 2013-03-14 2021-01-19 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN105307654B (zh) 2013-04-30 2022-06-07 托马斯·朱利叶斯·波洛迪 用于治疗微生物区系相关的精神病况和疾病的组合物和方法
EP3375447A1 (en) * 2013-06-05 2018-09-19 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9511100B2 (en) * 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
EP3052111B1 (en) 2013-10-03 2020-12-23 The Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
AU2014352643A1 (en) 2013-11-25 2016-06-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015124637A1 (en) 2014-02-18 2015-08-27 Conaris Research Institute Ag Methods and compositions for intestinal microenvironment transfer
US10293004B2 (en) 2014-03-28 2019-05-21 Kabushiki Kaisha Yakult Honsha Butyrate-producing bacterium and use thereof
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
SE1550189A1 (en) 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
CN114159476A (zh) * 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3297644B1 (en) 2015-05-22 2022-01-19 Arizona Board of Regents on behalf of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
EP3368050A1 (en) 2015-10-26 2018-09-05 Crestovo Holdings LLC Compositions and methods for fecal microbiota-related therapy
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
CA3026414A1 (en) 2016-06-01 2017-12-07 Crestovo Holdings Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2018089794A1 (en) 2016-11-11 2018-05-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for changing metabolite levels in a subject

Also Published As

Publication number Publication date
WO2016191356A1 (en) 2016-12-01
KR102534545B1 (ko) 2023-05-18
EP3998072A1 (en) 2022-05-18
US20200061148A1 (en) 2020-02-27
NZ776366A (en) 2023-02-24
KR20220021006A (ko) 2022-02-21
JP6856968B2 (ja) 2021-04-14
NZ737786A (en) 2022-07-01
US20160339065A1 (en) 2016-11-24
KR102358879B1 (ko) 2022-02-08
JP7273082B2 (ja) 2023-05-12
DK3297644T3 (da) 2022-04-11
CN108243608A (zh) 2018-07-03
US20220088089A1 (en) 2022-03-24
EP3297644B1 (en) 2022-01-19
AU2016268158B2 (en) 2022-03-17
CA2986485A1 (en) 2016-12-01
US20190328825A1 (en) 2019-10-31
PT3297644T (pt) 2022-03-30
CN114366759A (zh) 2022-04-19
AU2016268158A1 (en) 2017-12-14
HUE058209T2 (hu) 2022-07-28
ES2909456T3 (es) 2022-05-06
EP3297644A4 (en) 2018-12-05
JP2018515624A (ja) 2018-06-14
BR112017024777A2 (pt) 2018-08-07
JP2021100946A (ja) 2021-07-08
KR20180029967A (ko) 2018-03-21
CN114470009A (zh) 2022-05-13
EP3297644A1 (en) 2018-03-28
AU2022203294A1 (en) 2022-06-02
AU2022203294B2 (en) 2023-07-06
US11202808B2 (en) 2021-12-21
US20190134144A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
HUE058209T2 (hu) Módszerek az autizmus spektrum zavar és azzal összefüggõ tünetek kezelésére
HK1251407A1 (zh) 治療癌症的方法
ZA201705673B (en) Methods for treating skin
IL253573A0 (en) Combined therapies for the treatment of cancers
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1259342A1 (zh) 用於治療癌症的聯合療法
HK1244157A1 (zh) 頻譜共享架構和方法
HK1251965A1 (zh) 用於治療癲癇的方法
HK1250944A1 (zh) 用於治療癌症的方法
SG11201610551TA (en) Combinations for treating cancers
HK1252996A1 (zh) 用於治療癲癇的方法
GB2549277B (en) Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
IL254963A0 (en) Preparations and methods for the treatment of autism
IL255079A0 (en) Methods of treating lung cancer
HK1248135A1 (zh) 用於治療癌症的聯合方法
GB2549278B (en) Use of cannabidivarin in the treatment of autism spectrum disorder
HK1250942A1 (zh) 用於治療癌症的方法
GB201616609D0 (en) Spectroscopy method and system
HK1255939A1 (zh) 用於治療癌症之組合療法
HK1250943A1 (zh) 用於治療癌症的方法
IL249616A0 (en) Methods for treating inflammation
HK1256371A1 (zh) 用於治療腫瘤的方法
GB201400651D0 (en) Innovated method for treating eoble through inhaling ozone
GB201418526D0 (en) Kit and method for preventing or treating menopausal symptoms